THERAPY DOSSIER · th-ecc08f732367

Unsubstituted tricyclic phenothiazine

Drug · Parent phenothiazine scaffold (ChEMBL CHEMBL828); no discrete therapeutic MoA record; used here as an unsubstituted core

Not approved Suggest a correction

Evidence & regulatory context

Mechanism: Parent phenothiazine scaffold (ChEMBL CHEMBL828); no discrete therapeutic MoA record; used here as an unsubstituted core
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Preclinical/no trial
ChEMBL record: CHEMBL828 ↗
ChEMBL max phase: 2 / 4 (development scale, not regulatory approval)
Synonyms: Phenothiazine; 10H-phenothiazine
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25449871 ↗2014Mixed findings

The antioxidative, non-psychoactive tricyclic phenothiazine reduces brain damage after experimental traumatic brain injury in mice.

MouseTBIControlled cortical impactC57Bl6MaleSubcutaneous3 mg/kg (low dose) or 30 mg/kg (high dose)30 minutes after controlled cortical impact

Model: Pneumatic controlled cortical impact injury, with endpoints at 24 hours

Phenothiazine dose-dependently reduced lesion volume by about 20% at 3 mg/kg and 26% at 30 mg/kg and limited weight loss, with lower iNOS expression but no significant change in neurological score, Iba-1 cells or TNF-alpha.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…